Jung Eunsun, Choi Jinhyeon, Kim Jang-Seong, Han Tae-Su
Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
Pharmaceuticals (Basel). 2021 Feb 8;14(2):136. doi: 10.3390/ph14020136.
Although therapeutic approaches for patients with colorectal cancer (CRC) have improved in the past decades, the problem of drug resistance still persists and acts as a major obstacle for effective therapy. Many studies have shown that drug resistance is related to reduced drug uptake, modification of drug targets, and/or transformation of cell cycle checkpoints. A growing body of evidence indicates that several microRNAs (miRNAs) may contribute to the drug resistance to chemotherapy, targeted therapy, and immunotherapy by regulating the drug resistance-related target genes in CRC. These drug resistance-related miRNAs may be used as promising biomarkers for predicting drug response or as potential therapeutic targets for treating patients with CRC. In this review, we summarized the recent discoveries regarding anti-cancer drug-related miRNAs and their molecular mechanisms in CRC. Furthermore, we discussed the challenges associated with the clinical application of miRNAs as biomarkers for the diagnosis of drug-resistant patients and as therapeutic targets for CRC treatment.
尽管在过去几十年中，结直肠癌（CRC）患者的治疗方法有所改进，但耐药问题仍然存在，并且是有效治疗的主要障碍。许多研究表明，耐药性与药物摄取减少、药物靶点修饰和/或细胞周期检查点的转变有关。越来越多的证据表明，几种微小RNA（miRNA）可能通过调节CRC中与耐药相关的靶基因，导致对化疗、靶向治疗和免疫治疗产生耐药性。这些与耐药相关的miRNA可用作预测药物反应的有前景的生物标志物，或作为治疗CRC患者的潜在治疗靶点。在本综述中，我们总结了近期关于CRC中与抗癌药物相关的miRNA及其分子机制的发现。此外，我们讨论了将miRNA作为耐药患者诊断生物标志物和CRC治疗治疗靶点的临床应用所面临的挑战。
